PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.

NCT00908414 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped strategic decision

Conditions

HIV Infections

Interventions

DRUG: TMC589337 40 mg
DRUG: TMC589337 100 mg
DRUG: TMC589337 200 mg
DRUG: TMC589337 400 mg
DRUG: TMC589354 40 mg
DRUG: TMC589354 100 mg
DRUG: TMC589354 200 mg
DRUG: TMC589354 400 mg
DRUG: TMC589337 AA mg
DRUG: TMC589354 BB mg
DRUG: TMC589337 CC mg
DRUG: TMC589354 DD mg
DRUG: TMC589337 EE mg
DRUG: TMC589354 YY mg
DRUG: TMC310911 300 mg
DRUG: TMC310911 600 mg
DRUG: Placebo

Sponsor

Tibotec Pharmaceuticals, Ireland